HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

J. Biol. Chem., Vol. 276, Issue 45, 41870-41878, November 9, 2001

This Article Abstract Full Text (PDF) All Versions of this Article: 276/45/41870    most recent M107155200v1 Submit a Letter to Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Casula, S. Articles by Alper, S. L. Search for Related Content PubMed PubMed Citation Articles by Casula, S. Articles by Alper, S. L. Social Bookmarking                      What's this?

A Dominant Negative Mutant of the KCC1 K-Cl Cotransporter

BOTH N- AND C-TERMINAL CYTOPLASMIC DOMAINS ARE REQUIRED FOR K-Cl COTRANSPORT ACTIVITY^*

Sabina Casula^§, Boris E. Shmukler^¶, Sabine Wilhelm, Alan K. Stuart-Tilley, Wanfang Su, Marina N. Chernova^¶, Carlo Brugnara^§, and Seth L. Alper^¶**§§

From the  Molecular Medicine and ^** Renal Units, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215, the ^§ Department of Laboratory Medicine, The Children's Hospital, Boston, Massachusetts 02115, and the Departments of ^¶ Medicine,  Cell Biology, and  Pathology, Harvard Medical School, Boston, Massachusetts 02115

Received for publication, July 27, 2001

	ABSTRACT

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES

K-Cl cotransport regulates cell volume and chloride equilibrium potential. Inhibition of erythroid K-Cl cotransport has emerged as an important adjunct strategy for the treatment of sickle cell anemia. However, structure-function relationships among the polypeptide products of the four K-Cl cotransporter (KCC) genes are little understood. We have investigated the importance of the N- and C-terminal cytoplasmic domains of mouse KCC1 to its K-Cl cotransport function expressed in Xenopus oocytes. Truncation of as few as eight C-terminal amino acids (aa) abolished function despite continued polypeptide accumulation and surface expression. These C-terminal loss-of-function mutants lacked a dominant negative phenotype. Truncation of the N-terminal 46 aa diminished function. Removal of 89 or 117 aa (_N117) abolished function despite continued polypeptide accumulation and surface expression and exhibited dominant negative phenotypes that required the presence of the C-terminal cytoplasmic domain. The dominant negative loss-of-function mutant _N117 was co-immunoprecipitated with wild type KCC1 polypeptide, and its co-expression did not reduce wild type KCC1 at the oocyte surface. _N117 also exhibited dominant negative inhibition of human KCC1 and KCC3 and, with lower potency, mouse KCC4 and rat KCC2.

	INTRODUCTION

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES

Secondary active transport of chloride across cell plasma membranes is achieved by ion symport and antiport mechanisms. The major chloride symporters are members of the phylogenetically ancient CCC¹ cation chloride cotransporter superfamily, comprising in mammals two NKCC genes encoding multiple bumetanide-sensitive Na-K-2Cl cotransporter polypeptides (1, 2), one NCC gene encoding thiazide-sensitive NaCl cotransporter polypeptides (3), and at least four KCC encoding multiple K-Cl cotransporter polypeptides (4). K-Cl cotransporters in most cell types mediate solute efflux and regulatory volume decrease, opposing the solute import functions of NKCCs. K-Cl cotransporters also serve to regulate the cellular electrochemical equilibrium potential for Cl and can regulate [K⁺] of the interstitial space, especially in the nervous system. KCC1 cDNAs have been cloned from rabbits (5), rats (5), humans (5), pigs (6), and mice (7, 8), with gene structures reported for humans (6), mice (9), and Caenorhabditis elegans (6). KCC2 cDNA has been cloned from rat (10). Two isoforms of human KCC3 cDNA (11-13), KCC4 cDNA from humans and mice (13), and a Xenopus oocyte partial cDNA encoding a KCC isoform of the KCC1/3 family (14) have also been reported.

NKCCs are activated by hypertonic cell shrinkage and by activators of protein phosphorylation. NKCCs tend to be inhibited by cell swelling, by sulfhydryl oxidizing agents, and by inhibitors of protein dephosphorylation. In contrast, KCCs are activated by hypotonic cell swelling, by sulfhydryl oxidizing agents, and by inhibitors of protein phosphorylation. KCCs tend to be inhibited by cell shrinkage and by inhibitors of protein dephosphorylation (4). Heterologous overexpression of KCC1 leads to up-regulation of endogenous NKCC activity (15). The molecular mechanisms by which KCCs are regulated are unknown.

The transmembrane region of CCC polypeptides, based on data from NKCC1, probably spans the lipid bilayer 12 times (16). Transmembrane helices 2, 4, and 7 of NKCC1 have been implicated in ion binding by site-directed mutagenesis studies (17). The two initial reports on structure-function relationships of K-Cl cotransporters concern aspects of their C-terminal cytoplasmic tails. Tyr¹⁰⁸⁷ of rat KCC2, close to KCC2's C terminus, and the analogous residue in rabbit KCC1 are each required for hypotonic activation of ion transport activity in Xenopus oocytes. However, neither residue is required for delivery to the oocyte surface or for inhibition of hypotonically activated transport activity by serine-threonine phosphatase inhibitors (18). In addition, Lauf et al. (19) have shown that removal from Myc-tagged rabbit KCC1 of most of the C-terminal cytoplasmic domain abolished activation by N-ethylmaleimide (NEM) in HEK-293 cells while apparently decreasing but not abolishing surface expression.

Inhibition of the potassium efflux pathways mediating cell shrinkage has proven an increasingly important approach to the therapy of sickle cell disease. The major potassium efflux pathways of the sickle erythrocyte are K-Cl cotransport and the IK1 KCa channel (20). Although high potency inhibitors of the IK1 erythroid KCa channel are available, clinically tolerated (21), and in continued development, high potency inhibitors of K-Cl cotransport have not been identified. KCC inhibitors could serve as an adjunct treatment of sickle cell disease, as shown to date with clinical trials of oral magnesium supplementation (22). Such specific KCC inhibitors would also provide a useful experimental tool to test the role of K-Cl cotransport in cell function.

We have initiated structure-function studies with the 1085-aa mouse KCC1 K-Cl cotransporter. We show here that both the C-terminal cytoplasmic domain and the membrane-proximate portion of the N-terminal cytoplasmic domain are absolutely required for transport function in Xenopus oocytes. In addition, we show that removal of the entire N-terminal cytoplasmic domain from KCC1 confers a dominant negative phenotype that requires the presence of the C-terminal cytoplasmic domain. The dominant negative mutant polypeptide associates physically with the wild type KCC1 polypeptide and exhibits its dominant negative phenotype when co-expressed with other KCC gene products. This dominant negative mutant should provide useful information on the mechanism of regulation of KCC K-Cl cotransporters.

	EXPERIMENTAL PROCEDURES

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES

Polymerase Chain Reaction-- 500 ng of plasmid pXmKCC1 encoding wild type mKCC1 cDNA (7) was subjected to hot start PCR in a total reaction volume of 50 µl, using the Expand High Fidelity PCR System (Roche Molecular Biochemicals) in the supplier's recommended buffer. PCR mixes lacking only primers were preheated at 82 °C for 1 min, after which appropriate primers were injected into the mix through mineral oil. The complete reaction mixes were denatured for 5 min at 95 °C and then cycled through these conditions: denaturation for 45 s at 94 °C, annealing for 2 min at 60 °C, and elongation for 2 min at 72 °C. Final extension of 10 min at 72 °C was terminated by rapid cooling to 4 °C after 8-10 cycles. PCR products were analyzed in 1% agarose gels, purified from gel with the QIAquick Gel Extraction Kit (Qiagen), and cloned into the "T-vector" pCR2 (Invitrogen). DNA sequence integrity of the cloned PCR amplification products was verified with an ABI 373 DNA sequencer. DNA sequence analysis was carried out with the GCG suite of programs (University of Wisconsin Genetics Computing Group).

Construction of N-terminally Truncated (_N) KCC1 Mutants-- Each forward oligodeoxynucleotide primer encoded the native Kozak initiation sequence of mouse KCC1 (mKCC1) followed by the desired amino acids of the KCC1 N-terminal cytoplasmic tail. The forward primers used were KCC1.N46F (5'-CCAAGCGCGCGCGATGAGCCCTTTCCTTTGCCCTTTG-3'), KCC1.N89F (5'-CCAAGCGCGCGCGATGACCAACCTCACCCAAGGAG-3'), and KCC1.N117F (5'-CCAAGCGCGCGCGATGGGCACACTCATGGGAGTG-3'). Each of these was used for PCR in combination with the reverse oligonucleotide KCC1.E7R (7).

Plasmids encoding each full-length mKCC1 _N mutant were reconstructed by a three-way ligation of appropriate gel-purified EcoRI (pCR2-derived)/RcaI-cut fragment carrying the new mutation, RcaI/SpeI-cut pXmKCC1 encoding the remainder of mKCC1, and EcoRI/SpeI-cut pXT7 encoding the Xenopus oocyte expression vector backbone of pXmKCC1 (7). The mKCC1 _N mutants are summarized in Fig. 1. _N mutant nomenclature is illustrated by _N46, in which the mutant initiator Met replaces wild type mKCC1 Asn⁴⁶ and precedes wild type Ser⁴⁷.

View larger version (51K): [in this window] [in a new window]   Fig. 1.   Schematic diagram of mKCC1 constructs. Wild type mKCC1, N-terminal cytoplasmic truncation mutants N46, N89, and N117 and C-terminal cytoplasmic truncation mutants C1077, C940, C805, C698, and C660 are shown. Cyto (dark bars), N-terminal cytoplasmic domain; TM (gray bars), transmembrane domain; Cyto (white bars), C-terminal cytoplasmic domain. Amino acid residues at domain junctions are indicated within the wild type mKCC1 construct.

Construction of C-terminally Truncated (_C) KCC1 Mutants-- For construction of mKCC1 C-terminal truncation mutant _C660, forward primer KCC1.F7 (7) was used for PCR in combination with reverse primer KCC1._C660R1 (5'-CTAGTCAGTCACTCCTTCTCGGCCCCTTG-3'), introducing a termination codon in place of codon W661. To reconstruct the plasmid encoding full-length mKCC1 _C660, the PCR amplification product was subcloned into pCR2, excised with NcoI/SpeI, and ligated with the complementary NcoI/SpeI-cut fragment of pXmKCC1.

All other mKCC1 _C mutants were constructed by digestion at a convenient restriction site within the mKCC1 coding region (AflII for _C698, PmlI for _C805, HincII for _C940, or EagI for _C1077) and at the polylinker SpeI site. Gel-purified DNA was blunted and recircularized by self-ligation. These internal deletion plasmids added the following polylinker-encoded C-terminal amino acids to the mKCC1 coding regions: Asn to _C698, Phe to _C940, and Pro-Ser-Asp to _C805 and to _C1077. _C mutant nomenclature is illustrated by _C1077, in which the last wild type amino acid prior to the polylinker-encoded residues is mKCC1 Gly¹⁰⁷⁷. The double mutant _N117/_C805 was constructed by ligation of the NcoI-XbaI backbone fragment of _N117 with the complementary NcoI-XbaI fragment of _C805.

hKCC1, rKCC2, hKCC3, and mKCC4 cDNAs-- Rat KCC2 cDNA (10) was the gift of J. Payne (University of California, Davis, CA). Human KCC3 cDNA (12) was the gift of P. Dunham (Syracuse University) and E. Holtzman (Tel-Aviv). Mouse KCC4 cDNA was cloned by RT-PCR from mouse kidney cDNA. The 5'-primer used was 5'-CGGAGCCATGCCCACGAACTTTACGGTG-3', derived from GenBank^TM entry AF087436. The 3'-primer was KCC1.CT (7), encoding the C-terminal amino acid residues identical in KCC1 and KCC4 polypeptides.

Human KCC1 was cloned by RT-PCR from atrial appendage mRNA using as primers KCC1.NT and KCC1.CT (7). The integrity of the amplified mKCC4 and hKCC1 cDNAs was verified by DNA sequencing. A fragment encoding the hKCC1 splice variant lacking exon 18 (Ex18) was amplified from 293T cell RNA by RT-PCR using as primers KCC1.E16F and KCC1.E21R (7). The subcloned variant fragment was reconstructed into the pXT7-hKCC1 backbone by SacII-SpeI (pCR2-derived) restriction and ligation. All cDNAs were subcloned into the oocyte expression vector pXT7 (7).

Transcription and Translation of Wild Type and Truncated mKCC1 cRNAs and Polypeptides-- Capped cRNAs were transcribed with T7 polymerase from XbaI-linearized template (MEGAscript, Ambion) and purified (RNeasy kit, Qiagen). In vitro translation of polypeptide labeled with Tran³⁵S-Label (ICN) was performed with the nuclease-treated rabbit reticulocyte lysate system (Promega) in the presence of canine pancreatic microsomal membranes (Promega) in a 25-µl reaction volume, per manufacturer's protocol. Alternatively, coupled transcription-translation (TnT; Promega) was used. The reaction was terminated, and microsomes were solubilized by the addition of 80 µl of immunoprecipitation (IP) buffer: 150 mM NaCl, 5 mM EDTA, 10 mM Tris-HCl, pH 7.5, 1% Triton X-100, 0.5% sodium deoxycholate, and 2 mg/ml bovine serum albumin. SDS-polyacrylamide gel electrophoresis fluorography was as described (7).

cRNA Expression in Xenopus Oocytes-- Female Xenopus anesthetized with 0.17% Tricaine were subjected to partial ovariectomy. Excised, minced ovarian segments were incubated for 1 h with gentle shaking at room temperature in 2 mg/ml type A collagenase (Roche Molecular Biochemicals) in ND 96, pH 7.4, containing 96 mM NaCl, 2 mM KCl, 1.8 mM CaCl₂, 5 mM Hepes, and 2.5 mM sodium pyruvate, supplemented with 5 mg/100 ml gentamicin. Washed, manually defolliculated oocytes of stage V-VI were maintained at 19 °C. On the same day or the next day, oocytes were microinjected (Drummond manual microinjector) with 50 nl of water or solution containing 12.5 ng or the indicated quantity of cRNA. Oocytes were maintained in ND-96 plus gentamicin at 19 °C for 2-10 days, with daily change of medium (24), until used for ion transport assays.

⁸⁶Rb⁺ Influx Assay-- mKCC1 function was assessed by measurement of ⁸⁶Rb⁺ uptake into oocytes 4-10 days post-cRNA injection. Groups of 5-15 oocytes were preincubated in influx medium lacking isotope. The 60-min influx period was initiated by transfer of oocytes into 150 µl of medium containing 2.5-5 mCi of ⁸⁶RbCl. ⁸⁶Rb influx was terminated by five 50-ml washes at 4 °C in chloride-free medium lacking isotope. ⁸⁶Rb content of individual oocytes was determined in a  counter (Cobra AutoGamma, Packard). Aliquots of influx medium were counted for determination of specific activity.

All media contained 5 µM bumetanide and 200 µM ouabain to inhibit endogenous NKCC and Na,K-ATPase activities, respectively. Isotonic media were ND-96 or NMDG-96 (in which N-methyl-D-glucamine chloride substituted for sodium); results with either medium were indistinguishable. Chloride-free media contained gluconate salts. Hypotonic medium was NMDG-72. NEM was used at 1 mM.

Analysis of Influx Data-- Data for ⁸⁶Rb⁺ uptake were expressed as nmol of K⁺ × oocyte¹ × h¹ and presented as means ± S.E. for n experiments, each evaluating 5-25 individual oocytes. From a total of 84 independent experiments, five experiments were eliminated from analysis because of poor oocyte expression of wild type mKCC1 (a mean value of hypotonically activated ⁸⁶Rb⁺ uptake of <0.18 nmol of K⁺ × oocyte¹ × h¹, representing >2.7 S.D. below the mean). Among the total of 79 experiments analyzed, hypotonic stimulation was studied in 70 experiments, and stimulation by NEM was studied in 15 experiments. Group means were analyzed by two-tailed t tests, with correction for the 71 a priori meaningful pairwise comparisons (Microsoft Excel). p values so calculated were considered significant when <0.05.

Immunoblot Analysis of mKCC1 Polypeptide in Xenopus Oocytes-- 2-4 oocytes were suspended at 4 °C in oocyte lysis buffer (20 µl/oocyte) containing 1% Triton X-100, Complete^® protease inhibitor (Roche Molecular Biochemicals) and 50 mM Tris HCl, pH 8, 250 mM NaCl, 1 mM EDTA, and 1 mM phenylmethylsulfonyl fluoride. After 30 min of vigorous shaking at 4 °C, the extract was centrifuged 30 min at 4 °C in a microcentrifuge. Clarified lysate was fractionated by SDS-polyacrylamide gel electrophoresis (6 or 8% gels). Protein was subjected to immunoblot with affinity-purified rabbit polyclonal antibodies to mKCC1 N-terminal aa 1-14 and to mKCC1 C-terminal aa 1074-1085 and visualized by enhanced chemiluminescence (7).

Immunoprecipitation of mKCC1 Polypeptides from Xenopus Oocytes-- Oocytes were coinjected with 10 µCi of [³⁵S]methionine (1 mCi/ml) and with cRNA or water. 2-4 days later, groups of ~10 oocytes were manually homogenized at 4 °C in oocyte lysis buffer containing 500 mM NaCl (10 µl/oocyte) in a microcentrifuge tube with a fitted Teflon pestle (Kontes) and then subjected to 30 min of vigorous shaking and 10 min of centrifugation in a microcentrifuge at 4 °C. Clarified supernatants were brought to 250 mM NaCl and then precleared with 5% normal rabbit serum. Precleared supernatants were incubated overnight at 4 °C with affinity-purified anti-KCC1 antibodies (in the presence of 0.5% SDS only for anti-C-terminal antibodies), and immune complexes were precipitated with protein A-agarose. Pellets were washed at 4 °C six times in 1 ml of lysis buffer containing 500 ml NaCl and six more times in 1 ml of buffer without NaCl and then analyzed by SDS-polyacrylamide gel electrophoresis fluorography (25).

The same immunoprecipitation protocols were followed using 1% Triton X-100 extracts of wild type KCC1 and _N117 KCC1 after in vitro translation in the presence of pancreatic microsomes of [³⁵S]methionine-labeled protein.

Surface Biotinylation of KCC1 Polypeptides-- All procedures except polyacrylamide gel electrophoresis were conducted at 4 °C. Oocytes were subjected to three 2-min washes in phosphate-buffered saline (PBS), pH 9.0, and then incubated for 30 min in the same buffer supplemented with 0.5 mg/ml sulfosuccinimidyl-6-(biotinamido)hexanoate (Pierce). This solution was replaced with fresh solution, and incubation was continued for a second 30-min period. The biotinylated oocytes were washed and then quenched for 20 min in PBS containing 10 mM glycine. After three washes in ice-cold PBS, groups of five oocytes were homogenized in lysis buffer containing 150 mM NaCl, 20 mM, Tris, pH 7.4, 1% Triton X-100, 0.1% SDS, and Complete^® protease inhibitor.

After a 30-min incubation, the lysates were cleared by centrifugation. The cleared lysates were incubated with lysis buffer-prewashed streptavidin-acrylamide beads (10 µl) for 1 h with end-over-end rotation. The beads were washed three times in ice-cold lysis buffer containing 500 mM NaCl and washed three times in lysis buffer lacking NaCl and then mixed with SDS-loading buffer, electrophoresed on a 6% SDS-polyacrylamide gel, transferred to nitrocellulose, and subjected to immunoblot analysis.

Confocal Immunofluorescence Microscopy-- Five days after cRNA or water injection, 6-10 oocytes in each group, along with uninjected oocytes, were fixed in 1 ml of PBS containing 3% paraformaldehyde for 4 h at room temperature. Fixed oocytes were extensively rinsed with PBS, exposed to 1% SDS for 1-5 min, and then blocked for 1 h in PBS with 1% bovine serum albumin and 0.05% saponin. Overnight incubation with primary antibody was followed by several washes in PBS. After overnight incubation with secondary antibody and further washes in PBS, oocytes were dehydrated in methanol for 1 h and incubated overnight in BA:BB solution (23). 4-10 such oocytes expressing a single form or co-expressing two forms of KCC1 were aligned along a plexiglass groove and imaged with the Bio-Rad MRC-1024 laser-scanning confocal microscope. Images were acquired from at least two independent sets of cRNA injections for each KCC1 construct. Representative images of median intensity were compiled with Adobe Photoshop 5.0.

	RESULTS

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES

C-terminal Truncation of mKCC1 Leads to Loss of Function-- mKCC1 expressed in Xenopus oocytes was stimulated an average of 5.9-fold by hypotonic swelling (Fig. 2A, p < 0.001; the mean stimulation of just the heterologous KCC1-mediated (water-subtracted) component of ⁸⁶Rb⁺ influx was 8.6-fold). Even in isotonic conditions, ⁸⁶Rb⁺ influx was higher in oocytes expressing mKCC1 than in water-injected oocytes (p < 0.001). Our previous studies of mKCC1 in Xenopus oocytes (7) and other studies of rabbit (5, 19) and human KCC1 in 293 cells (6) and of native Xenopus oocyte K-Cl cotransport (14) have shown that this activated ⁸⁶Rb⁺ influx requires bath chloride and is inhibited by the serine-threonine phosphatase inhibitors okadaic acid and calyculin and by the diuretic diindenylalkanoic acid. Removal of only the eight C-terminal residues from the C-terminal cytoplasmic tail of mKCC1, as in _c1077, preserved a low level of activity in isotonic medium (p = 0.008) but abolished stimulation of ⁸⁶Rb uptake elicited by hypotonicity. More extensive truncation of the C-terminal cytoplasmic domain after residue 940, 805, 698, or 660 abolished activity (Fig. 2A).

View larger version (22K): [in this window] [in a new window]   Fig. 2.   mKCC1 C-terminal truncations lead to loss-of-function. A, 86Rb+ influx into oocytes expressing WT mKCC1 or the indicated C mutants, measured in isotonic () or hypotonic (+) medium. Values are means ± S.E. for n experiments, each evaluating 5-25 individual oocytes. For all C mutants, hypotonic and isotonic values are indistinguishable. B, 86Rb+ influx into oocytes expressing WT mKCC1 or the indicated C polypeptides, measured in isotonic medium in the absence () or presence of 1 mM NEM (+). Values are means ± S.E. for n experiments, each evaluating 5-20 individual oocytes. For all C mutants, NEM and control values are indistinguishable.

Treatment of oocytes with 1 mM NEM stimulated ⁸⁶Rb⁺ influx 2.1-fold in oocytes expressing wild type mKCC1 (p = 0.011) This stimulation was abolished by removal of the C-terminal eight amino acids and by all of the more extensive C-terminal truncations tested (Fig. 2B).

These mutant mKCC1 _C polypeptides accumulated in Xenopus oocytes to levels lower than for WT KCC1; _C940 polypeptide failed to accumulate to any detectable level (Fig. 3, A and B). Confocal immunofluorescence microscopy with anti-mKCC1 anti-peptide antibody directed against either cytoplasmic N-terminal aa 1-14 (NT) or cytoplasmic C-terminal aa 1074-1085 residues of mKCC1 (CT) detected wild type mKCC1 at or near the cell surface (Fig. 3B). CT antibody staining was greatly reduced in oocytes expressing mKCC1 _C1077 and was lost in oocytes expressing other _C mutants. However, NT staining suggested that _C1077, _C805, and _C660 retained considerable expression at or near the oocyte surface despite their loss of transport activity (Fig. 3B). The absence of staining in oocytes injected with mKCC1 _C940 (Fig. 3B) correlated with the absence of polypeptide on immunoblot (Fig. 3A). mKCC1 _C698 did not accumulate detectably at the oocyte surface despite its modest accumulation within the oocyte.

View larger version (30K): [in this window] [in a new window]   Fig. 3.   Oocyte expression of mKCC1 Cmutant polypeptides. A, NT immunoblot of WT and C mKCC1 polypeptide accumulation in total oocyte Triton X-100 lysate from 0.1 oocyte equivalent. B, confocal immunofluorescence images of oocytes expressing the indicated C mutants and immunostained with NT or CT antibodies. The image in each panel (1 mm2) represents the median staining intensity from among at least five oocytes.

Following construction and functional analysis of these engineered mKCC1 _C mutants, we found in the data base a variant hKCC1 transcript, expressed sequence tag AI 799106. The presence of the variant transcript was confirmed in human RNA from 293T cells (by DNA sequence) and in placenta and T84 cells (by RT-PCR with two primer pairs). In this transcript, selective deletion of exon 18 (hKCC1 Ex18) encodes a polypeptide in which Q747 (the terminal codon of exon 17) is followed by 33 novel, exon 19-encoded, frameshifted amino acid residues before termination at position 780 (GenBank^TM number AY026038). As is true for the engineered mKCC1 _C polypeptides, this physiological hKCC1 _C variant exhibited no detectable transport function in Xenopus oocytes (not shown). However, no Ex18 form of mKCC1 mRNA was detected by RT-PCR in mouse brain, heart, kidney, ES cells, and MEL cells.

N-terminal Truncation of mKCC1 Leads to Loss of Function-- The absence of the N-terminal 46 residues of mKCC1 (_N46 mKCC1) led to ⁸⁶Rb⁺ influx indistinguishable from that of WT mKCC1 but greater than in water-injected controls (Fig. 4, p < 0.001). _N46 mKCC1 exhibited diminished hypotonic activation of ⁸⁶Rb⁺ influx, 47% of wild type levels representing 3.3-fold stimulation of mKCC1-mediated influx (p  0.004 compared with hypotonically treated wild type mKCC1-expressing or water-injected oocytes; p < 0.05 for simple pairwise comparison with isotonic conditions, but >0.05 when corrected for 71 such comparisons). More extensive N-terminal deletion of 89 (_N89) or 117 residues (_N117) completely abolished activation of ⁸⁶Rb⁺ influx by hypotonicity (Fig. 4A). The 1.6-fold stimulation by NEM of ⁸⁶Rb⁺ influx into oocytes expressing mKCC1 _N46 was not statistically significant. As true for hypotonic stimulation, NEM stimulation and basal activity were also abolished by more extensive N-terminal truncation of mKCC1 (Fig. 4B).

View larger version (20K): [in this window] [in a new window]   Fig. 4.   mKCC1 N-terminal truncations lead to loss-of-function. A, 86Rb+ influx into oocytes expressing WT mKCC1 or the indicated N mutants measured in isotonic () or hypotonic (+) medium. Means ± S.E. for n experiments, each evaluating 5-25 oocytes, are shown. B, 86Rb+ influx into oocytes expressing WT mKCC1 or the indicated N mKCC1 polyeptides, measured in isotonic medium in the absence () or presence of 1 mM NEM (+). Means ± S.E. for n experiments, each evaluating 5-25 oocytes, are shown.

All _N mutant polypeptides accumulated to levels lower than wild type level (Fig. 5A). However, _N mutant polypeptides were present at or near the oocyte surface at levels similar to that of wild type mKCC1, as detected by confocal immunofluorescence microscopy with CT antibody (Fig. 5B). NT antibody failed to detect any N-terminally truncated mKCC1 polypeptide (Fig. 5B).

View larger version (43K): [in this window] [in a new window]   Fig. 5.   Oocyte expression of mKCC1 N mutant polypeptides. A, CT immunoblot of WT and C mKCC1 polypeptide accumulation in total oocyte Triton X-100 lysate from 0.1 oocyte equivalent. B, confocal immunofluorescence images of oocytes expressing the indicated C mutants and immunostained with NT or CT antibodies. The image in each panel (1 mm2) represents median staining intensity from among at least five oocytes.

The Loss-of-Function Mutant _C805 Is Not a Dominant Negative Mutant-- We tested the hypothesis that among the mKCC1 loss-of-function mutants generated by progressive deletion of C-terminal and N-terminal cytoplasmic tails might be one or more that exhibit a dominant negative phenotype. Wild type and _C805 mKCC1 were coexpressed in Xenopus oocytes and tested for transport function and for surface expression. Fig. 6A shows that even when expressed in a 3-fold molar excess of cRNA, mKCC1 _C805 did not inhibit hypotonicity-activated ⁸⁶Rb influx mediated by co-expressed wild type mKCC1. There was no statistical correlation between mole fraction of _C805 mKCC1 and ⁸⁶Rb⁺ influx (p = 0.10). Moreover, both mutant and wild type polypeptides were expressed at or near the cell surface, and mutant co-expression did not reduce the abundance of wild type mKCC1 at the oocyte periphery (Fig. 6B). Co-injection of oocytes with wild type mKCC1 and with any one of the mKCC1 mutants _C1077, _C698, or _C660 at 1:1 cRNA ratios similarly failed to inhibit wild type mKCC1-mediated ⁸⁶Rb⁺ uptake (not shown). We also tested the hypothesis that co-expression of _N and _C mKCC1 mutants might complement rescue function. However, co-expression of mKCC1 _N117 with mKCC1 _C805 did not rescue ⁸⁶Rb⁺ uptake stimulated by hypotonicity (not shown).

View larger version (28K): [in this window] [in a new window]   Fig. 6.   C805 mKCC1 is not a dominant negative mutant. A, coexpression of C805 mKCC1 with WT mKCC1, even at a 3-fold molar excess, does not inhibit hypotonically stimulated 86Rb+ influx. n experiments, each with 5-25 individual oocytes treated with hypotonic (open bars) or isotonic media (filled bars), are shown. B, confocal immunofluorescence images show that the inactive C805 mKCC1 is present at or near the oocyte surface and that its coexpression with WT mKCC1 does not greatly reduce wild type mKCC1 abundance at the oocyte surface. Each panel represents 1 mm2 and shows median staining intensity from among at least five oocytes.

The Loss-of-Function Mutant _N117 Is a Potent Dominant Negative Mutant-- Co-expression of the itself inactive mKCC1 mutant _N117 with an equal cRNA amount of wild type mKCC1 suppressed ⁸⁶Rb⁺ uptake by 80-90% (Figs. 7A and 8; p < 0.001). Co-expression of the inactive mKCC1 mutant _N89 with an equal cRNA amount of wild type mKCC1 produced a 50% decrease in activity (not shown). Expression of wild type mKCC1 polypeptide at or near the oocyte surface was not diminished by co-expression of mKCC1 _N117, itself present at or near the surface at WT levels (Fig. 7B). Fig. 7C shows that both WT KCC1 and _N117 KCC1 were biotinylated at the oocyte surface in comparable quantities (lanes 3 and 7), although biotin-accessible surface mKCC1 polypeptide represented a very small proportion of total oocyte mKCC1 (compare lane 1 with lane 3 and lane 6 with lane 7).² Moreover, abundance of neither total (lane 1) nor surface-biotinylated WT KCC1 (lane 3) was reduced by co-expression of _N117 KCC1 (lanes 4 and 5).² Thus, dominant negative suppression of WT KCC1 function by _N117 KCC1 is not achieved by diminution of WT KCC1 expression or surface accumulation.

View larger version (17K): [in this window] [in a new window]   Fig. 7.   N117 mKCC1 is a potent dominant negative mutant. A, co-expression of N117 mKCC1 at a 1:1 molar ratio with wild type mKCC1 inhibits hypotonically stimulated 86Rb+ uptake by more than 80%. n experiments, each with 5-25 individual oocytes treated with hypotonic (open bars) or isotonic media (filled bars), are shown. B, confocal immunofluorescence images show that the inactive N117 mKCC1 is present at or near the oocyte surface and that its co-expression with WT mKCC1 does not reduce WT polypeptide abundance at the oocyte surface. Each panel represents 1 mm2 and shows median staining intensity among at least five oocytes. C, surface biotinylation of mKCC1 and of N117 mKCC1 in oocytes expressing these polypeptides individually or together. Immunoblots with NT (upper blot) and CT antibodies (lower blot) compare KCC1 content in 0.1 oocyte equivalent of total lysate (C, lanes 1, 4, 6, and 8) with that in streptavidin precipitates from lysate of five oocytes previously treated without () or with (+) sulfosuccinimidyl-6-(biotinamido)hexanoate. One of four similar experiments is shown.

View larger version (14K): [in this window] [in a new window]   Fig. 8.   Concentration-response relationship of dominant negative suppression of K-Cl cotransport by N117 mKCC1. Increasing mole fractions of N117 produce increasing inhibition of WT mKCC1-mediated 86Rb+ influx. Amount of injected WT mKCC1 cRNA was held constant at 12.5 ng. Each diamond represents a single experiment evaluatating 5-25 individual oocytes. Mean values are indicated as horizontal lines among columns of diamonds. Some mole fractions are represented by a single experiment. Experiments with water-injected oocytes are indicated by circles at the right.

mKCC1 _N117 significantly suppressed function of co-expressed wild type mKCC1 in a dose-dependent manner, even at mole fractions of 0.1. When expressed at mole fractions of 0.5, mKCC1 _N117 completely suppressed function of wild type mKCC1 (Fig. 8; p < 0.001). Interestingly, the itself inactive compound truncation mutant, mKCC1 _N117/_C805, did not inhibit wild type mKCC1 function when co-expressed at a 1:1 cRNA ratio³ (not shown). Specificity of the dominant negative phenotype was also demonstrated by lack of suppression of WT KCC1-mediated ⁸⁶Rb⁺ influx by unrelated polytopic membrane transport proteins.⁴

mKCC1 _N117 Physically Associates with Wild Type mKCC1-- The dominant negative functional phenotype of _N117 mKCC1, as well as its co-expression with wild type mKCC1 at the oocyte surface, suggested that the mutant and the wild type polypeptides physically associate in the oocyte. This hypothesis was tested by co-immunoprecipitation experiments. As shown in Fig. 9A, in vitro translated ³⁵S-labeled wild type mKCC1 was immunoprecipitated by both NT and CT antibodies (lanes 1 and 4). In contrast, _N117 mKCC1 was precipitated only by CT antibody (lanes 2 and 5). When co-expressed, both WT and _N117 mKCC1 were present not only in the CT immunoprecipitate (lane 3) but also in the NT precipitate (lane 6), despite the absence of the N-terminal epitope in the _N117 polypeptide. This association of WT and _N117 mKCC1 was not evident when in vitro translation was carried out in the absence of microsomes or when separately translated polypeptides in microsomes were mixed and then detergent-solubilized (not shown).

View larger version (35K): [in this window] [in a new window]   Fig. 9.   Physical association of WT mKCC1 polypeptide with N117. A, immunoprecipitation of individually expressed [35S]Met-labeled wild type mKCC1 (lanes 1 and 4), N117 mKCC1 (lanes 2 and 5), or the two co-expressed polypeptides (lanes 3 and 6) from Triton X-100 lysates of microsomes harvested from in vitro translation reactions, using CT (C-t) or NT (N-t) antibodies. Lane 6 shows that NT antibody pulls down N117 in complex with WT mKCC1. B, immunoprecipitation of Triton X-100 lysates from 10 [35S]Met-labeled oocytes expressing either wild type mKCC1, N117, the co-expressed combination, or neither (H2O), using NT (N) or CT (C) antibodies. NT antibody pulls down N117 in complex with WT mKCC1 from lysate of oocytes in which the two polypeptides were co-expressed.

Physical association of WT and _N117 mKCC1 was also detected in oocytes (Fig. 9B). In detergent lysates from oocytes previously co-injected with cRNAs encoding _N117 and wild type mKCC1 polypeptides, the CT immunoprecipitate contained both polypeptides. As is true for in vitro co-translated polypeptides, the NT precipitate also contained both polypeptides, although its epitope was not present in mKCC1 _N117. This experiment, one of six similar co-precipitations, demonstrates physical association between _N117 and wild type KCC1 polypeptides in the Xenopus oocyte and suggests their direct interaction.

The nondominant negative loss-of-function mutant _C805 mKCC1 was not co-immunoprecipitated with wild type mKCC1 by CT antibody, despite the presence of the truncated polypeptide detected by NT antibody in detergent lysates of both microsomes and oocytes. Similarly, the double truncation mutant mKCC1 _N117/_C805 did not associate with WT mKCC1 in immunoprecipitates from lysates of metabolically labeled oocytes² (not shown).

_N117 mKCC1 Is a Potent Dominant Negative Suppressor of Co-expressed KCC3 and Less Potently Suppresses Co-expressed KCC4 and KCC2-- The KCC gene family has two branches, one represented by the closely related KCC1 and KCC3 (~77% identical) and the other comprising KCC2 and KCC4 (each about 65% identical to KCC1) (4, 26). Since single cell types can express more than one KCC gene product, the utility of a dominant negative KCC1 construct to inhibit K-Cl cotransporter activity in intact cells will depend on its ability to inhibit K-Cl cotransport activity mediated by the polypeptide products of other KCC genes.

Fig. 10A shows that mKCC1 _N117 at very low injected cRNA levels suppressed hypotonically stimulated activity of co-expressed wild type hKCC3 as potently as that of wild type mKCC1. mKCC1 _N89 also potently suppressed hypotonically stimulated activity of coexpressed hKCC3 (not shown). Fig. 10B shows that hypotonically stimulated activity of co-expressed wild type mKCC4 also was suppressed by mKCC1 _N117, although less potently than were KCC1 and hKCC3. KCC4 activity was inhibited 67% at a 1:1 cRNA ratio and 84% at a wild type/mutant cRNA ratio of 1:2. The higher functional activity of mKCC4 in Xenopus oocytes has been noted previously (26). Fig. 10C shows that hypotonically stimulated activity of rKCC2 was also inhibited by co-expressed mKCC1 _N117 but less potently still than against KCC4. 1:1 and 1:3 wild type/mutant ratios of injected cRNA ratios led to 31 and 67% inhibition, respectively, of KCC2 transport activity in hypotonic medium. Higher relative amounts of _N117 led also to rKCC2 inhibition in isotonic medium. Substantial basal activity of KCC2 in isotonic medium has been noted previously (18, 27).

View larger version (18K): [in this window] [in a new window]   Fig. 10.   N117 mKCC1 exhibits a dominant negative phenotype when co-expressed with polypeptide products of other KCC genes. A, N117 mKCC1 very potently suppresses 86Rb+ influx mediated by co-expressed hKCC3 activated by hypotonicity. B, N117 mKCC1 also suppresses 86Rb+ influx mediated by co-expressed mKCC4 activated by hypotonicity. C, N117 mKCC1 less potently suppresses 86Rb+ influx mediated by co-expressed rKCC2 activated by hypotonicity. Open bars, influx in hypotonic medium, filled bars, influx in isotonic medium. Values are means ± S.E. for n oocytes from two experiments. Injected mass ratios of cRNA are indicated for co-injected oocytes. Wild type cRNA injected was constant at 12.5 ng.

	DISCUSSION

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES

We have initiated structure-function analysis of the N-terminal and C-terminal cytoplasmic tails of the KCC1 K-Cl cotransporter. We have shown that removal of small terminal segments of either cytoplasmic tail sufficed to abrogate KCC1-mediated ⁸⁶Rb⁺ uptake into Xenopus oocytes stimulated either by hypotonicity or by 1 mM NEM. All C-terminal truncations exhibited loss-of-function phenotypes regardless of accumulation at or near the oocyte surface, but none displayed dominant negative properties.

Removal of the N-terminal 89 or 117 amino acids from mKCC1 also produced loss-of-function mutants that exhibit wild type levels of expression at or near the oocyte surface. The _N117 mKCC1 mutant proved to be a potent dominant negative inhibitor of wild type ion transport function while not decreasing wild type polypeptide abundance at the oocyte surface. The _N117 mutant and wild type polypeptides were associated in immunoprecipitates, whether prepared from oocytes in which they were co-expressed or from in vitro co-translation reactions in the presence of pancreatic microsomes. In contrast, the nondominant negative loss-of-function mutant _C805 polypeptide did not associate with wild type polypeptide in either setting. Both dominant negative suppression of wild type transport function by _N117 and the ability of _N117 to associate with wild type polypeptide required portions of the C-terminal tail beyond residue 805. _N117 mKCC1 also exhibited potent dominant negative inhibition of hKCC3-mediated ⁸⁶Rb⁺ uptake and, less potently, of ⁸⁶Rb⁺ uptake mediated by mKCC4 and rKCC2.

Functional Requirement for Both C-terminal and N-terminal Cytoplasmic Domains-- The requirement of the C-terminal residues for stimulation of mKCC1 by either hypotonicity or by NEM extends earlier findings on the importance of rabbit KCC1 Tyr¹⁰⁵⁶ and the analogous rat KCC2 Tyr¹⁰⁸⁷ to hypotonic stimulation (18). Our results also corroborate and extend those recently reported for NEM stimulation of rabbit KCC1 in HEK 293 cells (19). We have found that truncation of as few as eight C-terminal amino acids from mKCC1 abolished function without decrease in surface expression. Although all C-terminal truncation mutant polypeptides except _C940 accumulated in oocytes, distinct _C mutants were expressed at variable levels at the cell surface.

Following construction and functional analysis of our engineered mKCC1 _C mutants, we noted in the data base the variant hKCC1 expressed sequence tag AI 799106. In this transcript, selective deletion of exon 18 encodes a polypeptide in which Gln⁷⁴⁷ (the terminal codon of exon 17) is followed by 33 novel, exon 19-encoded, frameshifted amino acid residues before termination at position 780. The transcript is present in human RNA from 293T cells, T84 cells, and placenta. In agreement with all tested mKCC1 _C polypeptide mutants, this physiological hKCC1 _C variant exhibited no detectable transport function in Xenopus oocytes (not shown). Thus, our findings with engineered mKCC1 C-terminal truncation variants are relevant to at least one physiological hKCC1 transcript.

In contrast to the requirement for the entire C-terminal tail, removal of 46 N-terminal residues from mKCC1 preserved partial hypotonic stimulation. Retention of _N46 mKCC1 stimulation by NEM did not reach statistical significance. However, removal of 89 or 117 N-terminal residues abolished stimulation by both stimuli. These are the first data demonstrating a required role for the N-terminal cytoplasmic domain in KCC function. The N-terminal cytoplasmic domain, however, appears to be unnecessary for delivery to and accumulation of mKCC1 at the oocyte surface.

The N-terminal cytoplasmic tail of dogfish NKCC1 harbors a functional consensus binding site for protein phosphatase I, which dephosphorylates NKCC1 aa 184 to inactivate ion transport (28). This consensus sequence is absent from both cytoplasmic termini of mKCC1. However, many candidate phosphorylation sites are present within the N-terminal cytoplasmic region defined by deletion as critical for stimulation by hypotonicity or by NEM.

Oligomeric Structure of mKCC1-- Two observations support the hypothesis that recombinant mKCC1 exists as a homomultimer in Xenopus oocytes. First, the _N117 mutant of mKCC1 suppresses ion transport function of co-expressed wild type mKCC1. Second, the mutant and wild type polypeptides co-expressed in vitro and in oocytes can be co-immunoprecipitated by NT antibody that recognizes only wild type mKCC1. A homodimeric state has been proposed for rat parotid gland NKCC1 based on chemical cross-linking experiments (29). Chemical cross-linking and gel filtration also demonstrate covalent multimerization of mKCC1 as well as of other KCC gene products.⁵ NT immunoprecipitates contain an additional band of ~170 kDa, representing a distinct mKCC1-associated polypeptide absent from water-injected oocytes and not detected in CT immunoprecipitates (Fig. 9).

Dominant Negative Functions of CCC Family Members-- _N117 mKCC1 is the first reported dominant negative mutation among KCC K-Cl cotransporters and the first engineered dominant negative construct among CCCs. However, two examples of naturally occurring dominant negative CCCs have been reported. The first is the inactive C4 variants of mouse NKCC2, the shorter of two NKCC2 C-terminal polypeptide variants (30, 31). Co-expression of inactive C4 polypeptide (A4) with the longer and functionally active but cAMP-insensitive C9 variant of NKCC2 (F9) inhibited its cation transport activity in a manner that was partially reversed by cAMP-isobutylmethylxanthine (31). Since C4 and C9 isoforms of NKCC2 are coexpressed in mouse thick ascending limb of Henle (28), this interaction was proposed to underlie the ability of vasopressin to activate NKCC2 activity in thick ascending limb of the mouse kidney (31).

A second, naturally occurring, dominant negative form of CCC was found through functional characterization of a novel CCC cDNA identified in the expressed sequence tag data base and sharing 27% amino acid sequence identity with NKCC1 (32). Named CIP (for CCC-interacting protein, this transcript expressed in heart, placenta, brain, muscle, and kidney traffics to the cell surface, but is itself inactive as a transporter of rubidium or sodium. CIP selectively inhibited co-expressed NKCC1 but lacked dominant negative activity when co-expressed with the equally (remotely) homologous NKCC2 or with KCC1. Epitope-tagged heterologous CIP in lysates of transfected 293 cells could (in one condition) be co-immunoprecipitated with endogenous NKCC1 polypeptide.

Stoichiometric Considerations Arising from the Dominant Negative Phenotype of mKCC1 _N117-- The C4 variant of NKCC2 inhibited C9 NKCC2 activity only minimally in oocytes injected with equimolar quantities of cRNA but inhibited nearly completely when the C4/C9 ratio was 2:1 (31). A 1:1 ratio of injected CIP and NKCC1 cRNAs led to >80% inhibition of NKCC1 function (32). Inhibition by _N117 mKCC1 of co-expressed wild type mKCC1 and hKCC3 activities in oocytes (Figs. 7A, 8, and 10) was of comparable or greater potency.

Oligomeric stoichiometry of interaction between mutant and wild type membrane transport protein subunits in Xenopus oocytes is generally calculated based on relative mole fractions of injected cRNAs. Such calculations assume that the mass ratio of injected cRNAs reflects equivalent ratios of the encoded polypeptides at the cell surface or other interaction sites and further assume equivalent interaction affinities for homo- and hetero-oligomers. These assumptions are believed to be met for a growing number of both engineered (33) and genetically encoded dominant negative variants of homotetrameric K⁺ channels (34, 35) but remain inadequately tested for the interaction of _N117 KCC1 with WT KCC1 or for other dominant negative CCC interactions in heterologous expression systems. Modeling the mKCC1 coexpression data in Fig. 8 with the assumption of a binomial distribution of hetero- and homo-oligomers (33) does not discriminate between dimeric and tetrameric states (linear fit of the ln/ln plot of this data yields a slope 3.2 ± 0.9, not shown). Chemical cross-linking and gel filtration data⁵ indicate that all wild type KCC polypeptide gene products are at least homodimeric, consistent with the cross-linking of NKCC1 dimers (29). In addition, each mKCC1 truncation mutant examined in the current work can be covalently cross-linked to the homodimeric state.⁶ Thus, the presence of neither cytoplasmic domain of mKCC1 is required for homo-oligomerization.

Hetero-oligomeric Interactions among Polypeptide Products of Different KCC Genes-- The ability of _N117 mKCC1 potently to inhibit ion transport function of hKCC3 and less potently to inhibit mKCC4 and rKCC2 strongly suggests that the products of the different KCC genes can associate to form hetero-oligomeric polypeptides with considerable combinatorial complexity. Since the ion affinities, regulatory properties, and sensitivity to inhibitors varies among the different KCC gene products (4, 12, 26, 27), some of those macroscopic properties may also differ in cells expressing putative hetero-oligomers. This may be especially so for regulatory properties that might arise via altered affinity of homo-oligomeric (or hetero-oligomeric) interaction.

Utility of the _N117 mKCC1 Dominant Negative Mutant-- Specific and potent pharmacological inhibitors of KCC K-Cl cotransporters are currently unavailable. Correlative experiments examining changes in KCC isoform expression during whole animal physiological manipulations have been initiated (36). More direct tests of the physiological functions of KCC polypeptides and the consequences of loss of K-Cl cotransport activity will require knockout or knock-down experiments. These will involve either generation of homozygous knockout animals or transgenic expression of dominant negative or antisense constructs.

KCC K-Cl cotransporters are widely expressed among tissue and cell types. Some cell types probably express more than one KCC gene product. Thus, the possibility of functional compensation of a knockout of one gene product by unaltered or up-regulated expression of cognate genes is a serious one. In this setting, overexpression of _N117 or similar mutants offers a currently unique nonpharmacological tool for functional inhibition of all or most KCC gene products.

	ACKNOWLEDGEMENTS

We thank P. Dunham and J. Payne for the gifts of cDNA reagents.

	FOOTNOTES

^* This work was supported by Boston Sickle Cell Center Grant HL15157 (to C. B. and S. L. A.), Fellowship F32-HL09853 (to B. E. S.), Grant RO1-DK50422 (to C. B.), and Harvard Digestive Diseases Center Grant DK35854 (to S. L. A.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

^§§ To whom correspondence should be addressed: Molecular Medicine and Renal Units, RW763 East Campus, Beth Israel Deaconess Medical Center, 330 Brookline Ave., Boston, MA 02215. E-mail: salper@caregroup.harvard.edu.

Published, JBC Papers in Press, September 10, 2001, DOI 10.1074/jbc.M107155200

² In the immunoblot presented in Fig. 7C, apparent M_r values differ for _N117 mKCC1 in whole oocyte lysate (lanes 4 and 6) and in streptavidin precipitates from surface-biotinylated oocytes (lanes 5 and 7). This difference reflects the presence in whole oocyte lysate of abundant yolk platelet lipoproteins with M_r just above that of _N117, which consequently is displaced lower in the gel. These lipoproteins are essentially absent from the surface-biotinylated protein preparations in the streptavidin precipitates.

³ Since the epitope for neither NT nor CT antibodies was present in the mKCC1 compound truncation mutant _N117/_C805, the absence of dominant negative phenotype exhibited by this mutant could reflect either a requirement for the C-terminal cytoplasmic tail or too little accumulation of this mutant polypeptide.

⁴ A second criterion for specificity was examined by co-expression of either of two loss-of-function mutants of an unrelated polytopic membrane protein, the Cl/HCO exchanger eAE1. Neither mutant AE1 polypeptide itself increased ⁸⁶Rb⁺ influx into oocytes. The inactive human eAE1 mutant R760P (Band 3 Prague I), a cause of autosomal dominant hereditary spherocytosis, does not appear at the surface of the red blood cell or of the Xenopus oocyte and does not display a dominant negative anion exchanger phenotype (22). Similarly, AE1 Prague does not suppress mKCC1-mediated ⁸⁶Rb⁺ influx activity even when co-expressed at a 3-fold cRNA excess. In contrast, the mouse eAE1 mutant E699Q, inactive in the absence of sulfate, is expressed at the oocyte surface (23). As is true for hAE1 Prague, mAE1 E699Q did not suppress mKCC1-mediated ⁸⁶Rb⁺ influx activity.

⁵ S. Casula, A. S. Zolotarev, and S. L. Alper, unpublished observations.

⁶ S. Casula, A. S. Zolotarev, B. E. Shmukler, and S. L. Alper, unpublished results.

	ABBREVIATIONS

The abbreviations used are: CCC, cation chloride cotransporter; KCC, K-Cl cotransporter; NEM, N-ethylmaleimide; PCR, polymerase chain reaction; N, N-terminally truncated; C, C-terminally truncated; mKCC1, mouse KCC1; hKCC1, human KCC1; RT, reverse transcriptase; IP, immunoprecipitation; PBS, phosphate-buffered saline; WT, wild type; aa, amino acid(s).

	REFERENCES

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES

CiteULike

Complore

Connotea

Del.icio.us

Digg

Reddit

Technorati

This article has been cited by other articles:

				P. Uvarov, A. Ludwig, M. Markkanen, S. Soni, C. A. Hubner, C. Rivera, and M. S. Airaksinen Coexpression and Heteromerization of Two Neuronal K-Cl Cotransporter Isoforms in Neonatal Brain J. Biol. Chem., May 15, 2009; 284(20): 13696 - 13704. [Abstract] [Full Text] [PDF]

				M. Risinger, J. Rinehart, S. Crable, A. Ottlinger, R. Winkelmann, D. Pan, C. Huebner, P. G. Gallagher, and C. H. Joiner Structural and Functional Interactions of KCl Cotransport Proteins KCC1 and KCC3 in Sickle and Normal Erythrocyte Membranes Blood (ASH Annual Meeting Abstracts), November 16, 2008; 112(11): 2474 - 2474. [Abstract]

				M. Pedersen, M. Carmosino, and B. Forbush Intramolecular and Intermolecular Fluorescence Resonance Energy Transfer in Fluorescent Protein-tagged Na-K-Cl Cotransporter (NKCC1): SENSITIVITY TO REGULATORY CONFORMATIONAL CHANGE AND CELL VOLUME J. Biol. Chem., February 1, 2008; 283(5): 2663 - 2674. [Abstract] [Full Text] [PDF]

				Y.-M. Hsu, Y.-F. Chen, C.-Y. Chou, M.-J. Tang, J. H. Chen, R. J. Wilkins, J. C. Ellory, and M.-R. Shen KCl Cotransporter-3 Down-regulates E-Cadherin/{beta}-Catenin Complex to Promote Epithelial-Mesenchymal Transition Cancer Res., November 15, 2007; 67(22): 11064 - 11073. [Abstract] [Full Text] [PDF]

				L. De Franceschi, L. Ronzoni, M. D. Cappellini, F. Cimmino, A. Siciliano, S. L. Alper, V. Servedio, C. Pozzobon, and A. Iolascon K-CL co-transport plays an important role in normal and {beta} thalassemic erythropoiesis Haematologica, October 1, 2007; 92(10): 1319 - 1326. [Abstract] [Full Text] [PDF]

				C. H. Joiner, R. Kirk Rettig, M. Jiang, M. Risinger, and R. S. Franco Urea stimulation of KCl cotransport induces abnormal volume reduction in sickle reticulocytes Blood, February 15, 2007; 109(4): 1728 - 1735. [Abstract] [Full Text] [PDF]

				P. Blaesse, I. Guillemin, J. Schindler, M. Schweizer, E. Delpire, L. Khiroug, E. Friauf, and H. G. Nothwang Oligomerization of KCC2 Correlates with Development of Inhibitory Neurotransmission J. Neurosci., October 11, 2006; 26(41): 10407 - 10419. [Abstract] [Full Text] [PDF]

				D. S. Hekmat-Scafe, M. Y. Lundy, R. Ranga, and M. A. Tanouye Mutations in the K+/Cl- Cotransporter Gene kazachoc (kcc) Increase Seizure Susceptibility in Drosophila. J. Neurosci., August 30, 2006; 26(35): 8943 - 8954. [Abstract] [Full Text] [PDF]

				A. Mercado, V. Broumand, K. Zandi-Nejad, A. H. Enck, and D. B. Mount A C-terminal Domain in KCC2 Confers Constitutive K+-Cl- Cotransport J. Biol. Chem., January 13, 2006; 281(2): 1016 - 1026. [Abstract] [Full Text] [PDF]

				A. Mercado, N. Vazquez, L. Song, R. Cortes, A. H. Enck, R. Welch, E. Delpire, G. Gamba, and D. B. Mount NH2-terminal heterogeneity in the KCC3 K+-Cl- cotransporter Am J Physiol Renal Physiol, December 1, 2005; 289(6): F1246 - F1261. [Abstract] [Full Text] [PDF]

				G. M. Brunet, E. Gagnon, C. F. Simard, N. D. Daigle, L. Caron, M. Noel, M.-H. Lefoll, M. J. Bergeron, and P. Isenring Novel Insights Regarding the Operational Characteristics and Teleological Purpose of the Renal Na+-K+-Cl2 Cotransporter (NKCC2s) Splice Variants J. Gen. Physiol., September 26, 2005; 126(4): 325 - 337. [Abstract] [Full Text] [PDF]

				G. Gamba Molecular Physiology and Pathophysiology of Electroneutral Cation-Chloride Cotransporters Physiol Rev, April 1, 2005; 85(2): 423 - 493. [Abstract] [Full Text] [PDF]

				M. N. Chernova, L. Jiang, D. J. Friedman, R. B. Darman, H. Lohi, J. Kere, D. H. Vandorpe, and S. L. Alper Functional Comparison of Mouse slc26a6 Anion Exchanger with Human SLC26A6 Polypeptide Variants: DIFFERENCES IN ANION SELECTIVITY, REGULATION, AND ELECTROGENICITY J. Biol. Chem., March 4, 2005; 280(9): 8564 - 8580. [Abstract] [Full Text] [PDF]

				M.-R. Shen, A.-C. Lin, Y.-M. Hsu, T.-J. Chang, M.-J. Tang, S. L. Alper, J. C. Ellory, and C.-Y. Chou Insulin-like Growth Factor 1 Stimulates KCl Cotransport, Which Is Necessary for Invasion and Proliferation of Cervical Cancer and Ovarian Cancer Cells J. Biol. Chem., September 17, 2004; 279(38): 40017 - 40025. [Abstract] [Full Text] [PDF]

				G.-P. Zhou, C. Wong, R. Su, S. C. Crable, K. P. Anderson, and P. G. Gallagher Human potassium chloride cotransporter 1 (SLC12A4) promoter is regulated by AP-2 and contains a functional downstream promoter element Blood, June 1, 2004; 103(11): 4302 - 4309. [Abstract] [Full Text] [PDF]

				P. G.J.F. Starremans, F. F.J. Kersten, L. P.W.J. van den Heuvel, N. V.A.M. Knoers, and R. J.M. Bindels Dimeric Architecture of the Human Bumetanide-Sensitive Na-K-Cl Co-transporter J. Am. Soc. Nephrol., December 1, 2003; 14(12): 3039 - 3046. [Abstract] [Full Text] [PDF]

				M.-R. Shen, C.-Y. Chou, K.-F. Hsu, Y.-M. Hsu, W.-T. Chiu, M.-J. Tang, S. L. Alper, and J. C. Ellory KCl Cotransport Is an Important Modulator of Human Cervical Cancer Growth and Invasion J. Biol. Chem., October 10, 2003; 278(41): 39941 - 39950. [Abstract] [Full Text] [PDF]

				C. Vale, J. Schoorlemmer, and D. H. Sanes Deafness Disrupts Chloride Transporter Function and Inhibitory Synaptic Transmission J. Neurosci., August 20, 2003; 23(20): 7516 - 7524. [Abstract] [Full Text] [PDF]

				J. C. de Jong, P. H. G. M. Willems, F. J. M. Mooren, L. P. W. J. van den Heuvel, N. V. A. M. Knoers, and R. J. M. Bindels The Structural Unit of the Thiazide-sensitive NaCl Cotransporter Is a Homodimer J. Biol. Chem., June 27, 2003; 278(27): 24302 - 24307. [Abstract] [Full Text] [PDF]

				P. G.J.F. Starremans, F. F.J. Kersten, N. V.A.M. Knoers, L. P.W.J. van den Heuvel, and R. J.M. Bindels Mutations in the Human Na-K-2Cl Cotransporter (NKCC2) Identified in Bartter Syndrome Type I Consistently Result in Nonfunctional Transporters J. Am. Soc. Nephrol., June 1, 2003; 14(6): 1419 - 1426. [Abstract] [Full Text] [PDF]

				M. N Chernova, L. Jiang, B. E Shmukler, C. W Schweinfest, P. Blanco, S. D Freedman, A. K Stewart, and S. L Alper Acute regulation of the SLC26A3 congenital chloride diarrhoea anion exchanger (DRA) expressed in Xenopus oocytes J. Physiol., May 15, 2003; 549(1): 3 - 19. [Abstract] [Full Text] [PDF]

				M. N. Chernova, A. K. Stewart, L. Jiang, D. J. Friedman, Y. Z. Kunes, and S. L. Alper Structure-function relationships of AE2 regulation by Ca2+i-sensitive stimulators NH+4 and hypertonicity Am J Physiol Cell Physiol, May 1, 2003; 284(5): C1235 - C1246. [Abstract] [Full Text] [PDF]

				R. B. Darman and B. Forbush A Regulatory Locus of Phosphorylation in the N Terminus of the Na-K-Cl Cotransporter, NKCC1 J. Biol. Chem., September 27, 2002; 277(40): 37542 - 37550. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) All Versions of this Article: 276/45/41870    most recent M107155200v1 Submit a Letter to Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Casula, S. Articles by Alper, S. L. Search for Related Content PubMed PubMed Citation Articles by Casula, S. Articles by Alper, S. L. Social Bookmarking                      What's this?